SC
MRTX

Steven Cohen’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Steven Cohen’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200,000
Closed -$13.4M – 1812
2022
Q2 		$13.4M Buy
+200,000
New +$12.7M 0.06% 428
2019
Q4 		– Sell
-419,900
Closed -$32.7M – 1321
2019
Q3 		$32.7M Buy
+419,900
New +$39.4M 0.2% 146

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Steven Cohen's MRTX Position: Q4 2023 in Review

Steven Cohen sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 258,563 shares — an estimated $11.3M sold.

Steven Cohen first reported a position in MRTX in Q4 2017 and held it in 16 quarters. The position peaked at $70.4M in Q4 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Steven Cohen reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Steven Cohen sold 258,563 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $11.3M.
  • Steven Cohen first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 16 quarters.
  • Steven Cohen's Mirati Therapeutics, Inc. Common Stock position peaked at $70.4M in Q4 2021.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.